Extranodal nasal NK/T cell lymphoma

This phase II trial is testing whether adding the immunotherapy drug tislelizumab to a chemotherapy regimen (pegaspargase, gemcitabine, and oxaliplatin) plus radiation can improve outcomes for people with early-stage, intermediate- or high-risk extranodal NK/T-cell lymphoma. The …

This phase 2 trial is testing whether a combination of three drugs—sintilimab, pegaspargase, and anlotinib—can effectively treat stage IV extranodal NK/T-cell lymphoma in patients who are not healthy enough for high-intensity chemotherapy. The study enrolls adults with newly diag…

This trial is testing whether combining three drugs—camrelizumab, apatinib, and pegaspargase—with radiation therapy can improve outcomes for people with early-stage natural killer/T-cell lymphoma, a rare type of cancer. The study includes about 61 patients with stage IE or IIE di…

This phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…

This completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This early-phase trial tested whether adding the drug romidepsin before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Twenty-three patients received romidepsin along with standard chemotherapy, followed by a donor stem cell transpl…